pan-Canadian Oncology Drug Review
Final Economic Guidance Report

Blinatumomab (Blincyto) for Pediatric Acute Lymphoblastic Leukemia

August 23, 2017
DISCLAIMER
Not a Substitute for Professional Advice
This report is primarily intended to help Canadian health systems leaders and policymakers make well-informed decisions and thereby improve the quality of health care services. While patients and others may use this report, they are made available for informational and educational purposes only. This report should not be used as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision making process, or as a substitute for professional medical advice.

Liability
pCODR does not assume any legal liability or responsibility for the accuracy, completeness or usefulness of any information, drugs, therapies, treatments, products, processes, or services disclosed. The information is provided “as is” and you are urged to verify it for yourself and consult with medical experts before you rely on it. You shall not hold pCODR responsible for how you use any information provided in this report. Reports generated by pCODR are composed of interpretation, analysis, and opinion on the basis of information provided by pharmaceutical manufacturers, tumour groups, and other sources. pCODR is not responsible for the use of such interpretation, analysis, and opinion. Pursuant to the foundational documents of pCODR, any findings provided by pCODR are not binding on any organizations, including funding bodies. pCODR hereby disclaims any and all liability for the use of any reports generated by pCODR (for greater certainty, “use” includes but is not limited to a decision by a funding body or other organization to follow or ignore any interpretation, analysis, or opinion provided in a pCODR report).

FUNDING
The pan-Canadian Oncology Drug Review is funded collectively by the provinces and territories, with the exception of Quebec, which does not participate in pCODR at this time.
INQUIRIES

Inquiries and correspondence about the pan-Canadian Oncology Drug Review (pCODR) should be directed to:

pan-Canadian Oncology Drug Review
154 University Avenue, Suite 300
Toronto, ON
M5H 3Y9

Telephone: 613-226-2553
Toll Free: 1-866-988-1444
Fax: 1-866-662-1778
Email: info@pcodr.ca
Website: www.cadth.ca/pcodr
## TABLE OF CONTENTS

DISCLAIMER ................................................................................................................. ii
FUNDING .................................................................................................................... ii
INQUIRIES .................................................................................................................. iii

TABLE OF CONTENTS ..................................................................................................... iv

1 **ECONOMIC GUIDANCE IN BRIEF** ................................................................................. 1
   1.1 Submitted Economic Evaluation ............................................................................ 1
   1.2 Clinical Considerations ....................................................................................... 3
   1.3 Submitted and EGP Reanalysis Estimates ................................................................. 4
   1.4 Detailed Highlights of the EGP Reanalysis ............................................................... 5
   1.5 Evaluation of Submitted Budget Impact Analysis .................................................. 6
   1.6 Conclusions ..................................................................................................... 6

2 **DETAILED TECHNICAL REPORT** ................................................................................. 7
   This section outlines the technical details of the pCODR Economic Guidance Panel’s evaluation of the economic evidence that is summarized in Section 1. Pursuant to the pCODR Disclosure of Information Guidelines, this section is not eligible for disclosure. It was provided to the pCODR Expert Review Committee (pERC) for their deliberations.

3 **ABOUT THIS DOCUMENT** ......................................................................................... 8

REFERENCES ................................................................................................................ 9
1 ECONOMIC GUIDANCE IN BRIEF

1.1 Submitted Economic Evaluation

The economic analysis submitted to pCODR by Amgen Canada compared blinatumomab to standard of care for pediatric patients with relapsed/refractory (R/R) Philadelphia chromosome negative (Ph-) acute lymphoblastic leukemia (ALL).

Table 1. Submitted Economic Model

<table>
<thead>
<tr>
<th>Funding Request/Patient Population Modelled</th>
<th>Funding request matches patient population modeled and that of the phase I/II clinical trial. Relapsed/refractory disease was defined according to the Study MT103-205 trial, as follows:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Refractory to other treatments;</td>
<td>• Refractory to other treatments;</td>
</tr>
<tr>
<td>o Patients in first relapse must have</td>
<td>o Patients in first relapse must have failed to achieve a CR following full standard reinduction chemotherapy regimen of at least 4 weeks duration</td>
</tr>
<tr>
<td>failed to achieve a CR following full</td>
<td>o Patients who have not achieved a first remission must have failed a full standard induction regimen</td>
</tr>
<tr>
<td>standard reinduction chemotherapy</td>
<td>• Any marrow relapse after allogeneic HSCT; or</td>
</tr>
<tr>
<td>regimen of at least 4 weeks duration</td>
<td>• Second or later bone marrow relapse</td>
</tr>
<tr>
<td>• Any marrow relapse after allogeneic</td>
<td></td>
</tr>
<tr>
<td>HSCT; or</td>
<td></td>
</tr>
<tr>
<td>• Second or later bone marrow relapse</td>
<td></td>
</tr>
</tbody>
</table>

Type of Analysis  CUA & CEA

Type of Model  Partitioned-survival model

Comparator  Based on the CGP input, there is no single accepted standard of care for this patient population. For the purposes of the economic evaluation, a historical comparator, study 20140228 (standard of care consisting of salvage multi-drug chemotherapy) was used

Year of costs  2016

Time Horizon  Lifetime (95 years)

Perspective  Canadian health care payer

Cost of blinatumomab

• The unit cost of blinatumomab is $2,978.26 per 38.5 mcg of lyophilized powder in a single-use vial for reconstitution.
• In the MT103-205 trial, on average, subjects initiated two cycles of blinatumomab, and consumed 1.4 cycles, which corresponds to 39 vials (assuming one vial per day on blinatumomab treatment). The cost of 39 vials is $116,152.

The cost of blinatumomab per 28-day course is $55,594.20 (This includes 4 weeks of continuous IV infusion. Each cycle of treatment is separated by a two week treatment-free interval).
Cost of standard of care consisting of salvage multi-drug chemotherapy


There is no standard of care (SOC) for pediatric patients with relapsed/refractory Ph- ALL.

The SOC consists of salvage multi-drug chemotherapy. Based on cost data from Quintiles IMS Delta PA, the cost for initial induction and two consolidation blocks are as follows:

- UK R3 ALL: $6,469.81
- COG-AALL 1331: $15,605.91
- COG-AALL 0031: $11,004.95

Based on cost data from Quintiles IMS Delta PA, the cost of clofarabine is $128.96 per mg or $31,852.01 per phase.

In the submitted model, the unit costs of each component of the chemotherapy regimens were based on cost data from McKesson Canada and the Ontario Drug Benefit Formulary, as well as Canadian distributors and manufacturers. The average cost for the combined therapies was $11,246.

- The cost for initial induction and two consolidation blocks are as follows:
  - UK R3 ALL: $13,678.73
  - COG-AALL 1331: $16,371.77
  - COG-AALL 0031: $3,686.60

The cost of clofarabine was not included in the submitted base case. Based on the manufacturer of clofarabine, the total cost of clofarabine is $128.96 per mg or $31,885.54 per phase.

Model Structure

Three distinct health states included: remission (complete remission), progressive disease (includes progressive disease, aplastic bone marrow or partial remission), and death. Patients who survive for 60 months in the treatment phase were assumed to be cured.

Key Data Sources

Study MT103-205 (phase 1 & phase 2) to inform intervention arm
Study 20140228 to inform comparator arm

NOTE: there is no RCT to inform this economic model

Notes: *Cost for one cycle for a pediatric patient at 8 years of age with a body surface area of 0.95; ^ 52 mg/m² x 5 doses; ~ Based on the recommended dose of clofarabine (52 mg/kg); + Costs are calculated based on patients weighing > 45 kg (fixed dose). Dosage for patients weighing < 45 kg is based on body surface area.
1.2 Clinical Considerations

According to the pCODR Clinical Guidance Panel (CGP), this comparison is appropriate, given the absence of phase III data. The CGP noted that historical comparisons are not ideal. The CGP noted that a phase 3 randomized controlled trial is currently underway and will provide evidence on the role of blinatumomab in first line relapsed pediatric ALL.

Relevant issues identified included:

- There may be a net clinical benefit.
- Interpretation of non-comparative results using historical controls should be interpreted with caution.
- There is no data on the impact of blinatumomab on the quality of life of pediatric ALL patients.
- Although patients may be able to receive blinatumomab in the outpatient setting, the supportive care and pharmacy requirements for pediatric patients with relapsed/refractory ALL who are receiving blinatumomab would likely require pediatric patients to remain in close proximity of the hospital due to the support required during the course of therapy (e.g. transfusion support, portable infusion pump, nursing care for pump maintenance). Further, pediatric centres that do not have the appropriate outpatient resources to administer and monitor blinatumomab will require patients to be treated as an inpatient beyond the initial cycle of therapy.

Summary of registered clinician input relevant to the economic analysis
Registered clinicians supported the use of multi-drug chemotherapy and clofarabine-based regimens as appropriate comparators for this population. Additionally, alloHSCT, off study compassionate access to therapy or experimental therapy in a clinical trial setting were noted as options for relapsed/refractory pediatric patients. Registered clinicians stated that there are very few (if any) long term toxicities associated with blinatumomab compared to chemotherapy. There is, however, the possibility of short term neurotoxicity that can be severe. Registered clinicians also felt that blinatumomab is also at least as effective as conventional chemotherapy for this patient population.

Summary of patient input relevant to the economic analysis
Patients, via their caregivers, considered the side effects of treatments as an important consideration; adverse events were not incorporated into the model. Caregivers of patients also considered the societal costs of the disease as important; these were not considered as the economic model was constructed from the government payer perspective. Patients/caregivers are seeking treatment to achieve disease remission and to stop disease progression; overall survival and time in remission were considered in the economic model.

Summary of Provincial Advisory Group (PAG) input relevant to the economic analysis
PAG considered the following factors important to consider if implementing a funding recommendation for blinatumomab which are relevant to the economic analysis:

**Enablers**
- New class of drug that fills gap in therapy for pediatric relapsed/refractory ALL.

**Barriers**
- Unusual dosing schedule of 28-day continuous infusion with 2 weeks off.
• Resource intensive preparation and administration (e.g. different infusion durations per preparation bag [between 24-96 hours], different pump infusion rates with different durations of infusion, etc.).
• High rate of toxicities, particularly neurotoxicities, to monitor and treat.
• Hospitalization for administration of blinatumomab for the first cycle and for the first two days of the second cycle; proximity to tertiary care centres required.
• High cost of drug.
• Pre-medications required prior to first dose of each cycle.
• Multiple clinic visits for infusion bag to be changed and multiple visits required to prepare infusion bags during the four week infusion period.
• Drug wastage would be an issue as there is only one vial size of blinatumomab, and dosages are much smaller for pediatric patients (e.g., patients who weigh less than 45 kg).
• Since the stability of the reconstituted vials is 24 hours refrigerated and the stability of the prepared infusion bags is 10 days refrigerated, one vial can be used to prepare more than one infusion bag. However, 5.5mL of stabilizer is required to prepare each infusion bag and there is only 10mL of stabilizer included with each vial of drug. Thus, to prepare additional bags from one vial of drug, additional stabilizer is required from a different package. Therefore, wastage is a concern where partial vials may be used as the amount of stabilizer available within each package of blinatumomab is only sufficient for one infusion preparation.
• Portable, programmable, lockable infusion pumps used to administer blinatumomab in the outpatient setting may not be readily available in all treatment centres.

1.3 Submitted and EGP Reanalysis Estimates

<table>
<thead>
<tr>
<th>Estimates (range/point)</th>
<th>Submitted</th>
<th>EGP Reanalysis Lower Bound</th>
<th>EGP Reanalysis Upper Bound</th>
</tr>
</thead>
<tbody>
<tr>
<td>ΔE (LY)</td>
<td>4.98</td>
<td>8.64</td>
<td>1.30</td>
</tr>
<tr>
<td>Remission</td>
<td>0.85</td>
<td>1.47</td>
<td>0.24</td>
</tr>
<tr>
<td>Progressive disease</td>
<td>-0.05</td>
<td>-0.08</td>
<td>-0.03</td>
</tr>
<tr>
<td>Cure (after 5 years)</td>
<td>4.19</td>
<td>7.25</td>
<td>1.08</td>
</tr>
<tr>
<td>ΔE (QALY)</td>
<td>4.26</td>
<td>7.38</td>
<td>1.11</td>
</tr>
<tr>
<td>Remission</td>
<td>0.68</td>
<td>1.18</td>
<td>0.20</td>
</tr>
<tr>
<td>Progressive disease</td>
<td>-0.02</td>
<td>-0.03</td>
<td>-0.01</td>
</tr>
<tr>
<td>Cure (after 5 years)</td>
<td>3.60</td>
<td>6.23</td>
<td>0.93</td>
</tr>
<tr>
<td>ΔC ($)</td>
<td>$67,913</td>
<td>$48,572</td>
<td>$112,363</td>
</tr>
<tr>
<td>ICER estimate ($/QALY)</td>
<td>$15,940</td>
<td>$6,577</td>
<td>$100,948</td>
</tr>
</tbody>
</table>

The main assumptions and limitations with the submitted economic evaluation were:
• The main limitation of this economic model is the lack of comparative effectiveness data and the resulting uncertainty in relative efficacy between the two treatment arms. The three comparators chosen were from a historical comparator. Age was not used as a strata to adjust between the two comparator arms. The CGP indicated that age is an important effect modifier for pediatric ALL. Further, one of the regimens considered in the historical comparator (COG-AALL 0031) is not considered appropriate by the CGP.
• Small sample size for efficacy data for blinatumomab, which may lead to bias in generalizability.
• Quality of data in the historical comparator due to variables missing not at random for duration of response. This implies that the value of the variable that is missing is related to the reason it is missing.

• Uncertainty around duration of treatment for blinatumomab.

1.4 Detailed Highlights of the EGP Reanalysis

The EGP made the following changes to the submitted economic model:

• Time horizon: The economic model assumes that patients enter at 8 years of age and are “cured” if they are alive at 60 months. The base case then assumes a time horizon of 95 years from this point. The EGP elected to reduce the time horizon to 70 years (from cure), as these patients will most likely have late effects from chemotherapy, increasing their morbidity and most likely the mortality when adults (compared to the general population). The likelihood of any person in the general Canadian population living to 108 years old is very unlikely (as in the submitted base case).

• Comparator: The submitter assumed in the base case an equal split (i.e., 1/3) between UK R3 ALL, COG-AALL 1331 and COG-AALL 0031 regimens, excluding clofarabine. The CGP indicated that although clofarabine is not a first choice among clinicians due to the associated toxicities, it is a possible comparator. Further, the CGP indicated that COG-AALL 0031 regimen is not a likely choice in the relapsed/refractory setting. The EGP, based on the feedback from the CGP, made changes to the comparator to include clofarabine (33%), and exclude COG-AALL 0031 as part of the reanalysis.

• Overall survival hazard ratio: Given the lack of comparative effectiveness data, and the limitations noted in the chosen comparators and data used, the EGP elected to examine the uncertainty of overall survival by using the lower and upper bound of overall survival in the reanalysis estimates.

• Hospital length of stay during treatment with blinatumomab: The CGP noted that not all centres will have access to portable infusion pumps for their patients. In order to examine a conservative estimate, the EGP examined as an upper bound a scenario where patients receive blinatumomab only in a hospital setting, which translates to a length of stay of 60 days in hospital (instead of base case of 30 days in hospital, with the remainder using a portable infusion pump in the outpatient setting).

Table 3. EGP Reanalysis Estimates

<table>
<thead>
<tr>
<th>Description of Reanalysis</th>
<th>ΔC</th>
<th>ΔE QALYs</th>
<th>ICUR QALYs</th>
<th>Δ from baseline submitted ICER</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baseline</td>
<td>$67,913</td>
<td>4.26</td>
<td>$15,940</td>
<td>-</td>
</tr>
</tbody>
</table>
1.5 Evaluation of Submitted Budget Impact Analysis

The factors that most influence the budget impact analysis include the treatment duration (i.e. the number of vials of blinatumomab to be used). Increasing the number of vials to 45, from 39, increases the incremental three-year costs.

Key limitations of the BIA model include the lack of inclusion of drug administration costs, which could be significant for blinatumomab. However, these administration costs may not be more incrementally expensive than current standard of care chemotherapy. This parameter was not able to be modified and explored by the EGP.

1.6 Conclusions

The EGP’s best estimate of ΔC and ΔE for blinatumomab when compared to the standard of care given the submitted model is:
- Between $6,577/QALY and $100,948/QALY
- The extra cost of blinatumomab is between $48,572 and $112,363. The factors that most influence ΔC are the hospital length of stay for either blinatumomab or the standard of care, the cost per day for an inpatient stay, the number of vials of blinatumomab consumed and the choice of composition of the comparator.
- The extra clinical effect of blinatumomab is between 1.11 and 7.38 (ΔE). The factors that influence ΔE are the hazard ratio for overall survival and the utility for long-term survival.
- The CGP noted that the estimates of comparative efficacy derived from the comparison of the single arm MT103-205 trial with historical data should be interpreted with extreme caution. The comparison with a historical comparator is the best current available data for this limited population.
- Additionally, the EGP was not able to modify various important model parameters that were noted to potentially have an impact on the clinical effectiveness estimates.

Overall conclusions of the submitted model:
- Though the submitted model is fully functional and captures the majority of key inputs, there is too much uncertainty in the comparative effectiveness that cannot be captured in the reanalysis. For example, if there was no overall survival benefit between blinatumomab and the historical comparator, the ICER approaches $9 million.
- The use of a historical comparator limited the data available for the economic model. However, due to challenges in performing clinical trials in the pediatric population, the EGP performed reanalysis estimates despite the numerous limitations of assumptions in the economic model.
- This pediatric economic model has the potential for relatively large magnitude of gains for effects (submitted base case = 4.26 QALYs), given that ALL can be cured and a pediatric patient could continue to live for more than 60 years beyond cure.
- The large gains in efficacy translate into a relatively lower submitted base case ICER. The EGP cautions that the upper bound of the reanalysis estimate may exceed that provided in this report.
- Information from direct comparative trials with longer follow-up is still warranted.
2 DETAILED TECHNICAL REPORT
This section outlines the technical details of the pCODR Economic Guidance Panel’s evaluation of the economic evidence that is summarized in Section 1. Pursuant to the pCODR Disclosure of Information Guidelines, this section is not eligible for disclosure. It was provided to the pCODR Expert Review Committee (pERC) for their deliberations.
3 ABOUT THIS DOCUMENT

This Economic Guidance Report was prepared by the pCODR Economic Guidance Panel and supported by the pCODR pediatric Leukemia Clinical Guidance Panel and the pCODR Methods Team. This document is intended to advise the pCODR Expert Review Committee (pERC) regarding resource implications and the cost-effectiveness of blinatumomab (Blincyto) for relapsed/refractory Philadelphia negative pediatric ALL. A full assessment of the clinical evidence of blinatumomab (Blincyto) for relapsed/refractory Philadelphia negative pediatric ALL is beyond the scope of this report and is addressed by the relevant pCODR Clinical Guidance Report. Details of the pCODR review process can be found on the pCODR website (www.cadth.ca/pcodr).

pCODR considers it essential that pERC recommendations be based on information that can be publicly disclosed. Information included in the Economic Guidance Report was handled in accordance with the pCODR Disclosure of Information Guidelines. There was no information redacted from this publicly available Guidance Report.

This Final Economic Guidance Report is publicly posted at the same time that a pERC Final Recommendation is issued. The Final Economic Guidance Report supersedes the Initial Economic Guidance Report. Note that no revisions were made in between posting of the Initial and Final Guidance Reports.

The Economic Guidance Panel is comprised of economists selected from a pool of panel members established by the pCODR Secretariat. The panel members were selected by the pCODR secretariat, as outlined in the pCODR Nomination/Application Information Package and the Economic Guidance Panel Terms of Reference, which are available on the pCODR website (www.cadth.ca/pcodr). Final selection of the pool of Economic Guidance Panel members was made by the pERC Chair in consultation with the pCODR Executive Director. The Economic Guidance Panel is editorially independent of the provincial and territorial Ministries of Health and the provincial cancer agencies.
REFERENCES
